Cyclodextrins are known for their pharmaceutical applications in a range of pathologies. Beta(ꞵ)-cyclodextrins have been suggested to be effective scaffolds that can ligate to peptides when chemically modified, which has the potential to be cost-effective in comparison to other available treatments for antiviral therapeutics. It is hypothesized that a ꞵ-cyclodextrin platform can be modified through a few-step reaction process to develop a ꞵ-cyclodextrin-DBCO-GFP nanobody. The findings of this few-step reaction support the general approach of conjugating the ꞵ-cyclodextrin derivative to GPF nanobody for developing a cyclodextrin antiviral scaffold.